33,184 Shares in Cellebrite DI Ltd. (NASDAQ:CLBT) Acquired by Jennison Associates LLC

Jennison Associates LLC bought a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 33,184 shares of the company's stock, valued at approximately $645,000.

Several other large investors also recently made changes to their positions in CLBT. Catalyst Capital Advisors LLC bought a new stake in shares of Cellebrite DI during the 1st quarter worth about $51,000. Gen Wealth Partners Inc bought a new stake in shares of Cellebrite DI during the 4th quarter worth about $85,000. NewEdge Advisors LLC lifted its position in shares of Cellebrite DI by 600.7% during the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after purchasing an additional 3,352 shares during the last quarter. Sigma Planning Corp acquired a new position in shares of Cellebrite DI during the 1st quarter worth about $233,000. Finally, Victory Capital Management Inc. acquired a new position in shares of Cellebrite DI during the 4th quarter worth about $234,000. Institutional investors own 45.88% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Needham & Company LLC reissued a "buy" rating and set a $24.00 price objective on shares of Cellebrite DI in a research report on Friday, June 6th. JPMorgan Chase & Co. cut their price objective on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, May 12th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $22.43.

Cellebrite DI Stock Performance

Shares of CLBT stock traded down $0.10 during trading hours on Thursday, hitting $14.61. The company had a trading volume of 854,939 shares, compared to its average volume of 1,578,600. Cellebrite DI Ltd. has a 12 month low of $11.90 and a 12 month high of $26.30. The firm has a market capitalization of $3.50 billion, a price-to-earnings ratio of -15.24, a PEG ratio of 2.88 and a beta of 1.28. The firm's fifty day moving average is $15.91 and its 200 day moving average is $18.83.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.01. Cellebrite DI had a positive return on equity of 35.36% and a negative net margin of 46.34%. The company had revenue of $107.55 million for the quarter, compared to analyst estimates of $109.36 million. During the same period in the prior year, the company posted $0.08 EPS. The company's revenue was up 20.0% compared to the same quarter last year. On average, sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.